GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.

A series of stories that looks at the breakthroughs, setbacks, and overall status of vaccines and cures for hard-to-treat ...

Gilead Sciences’ top money maker Biktarvy has been the company’s crown jewel for years now, but with the HIV med inching ...

Some antibody-drug conjugates may cause such significant ocular toxicity that patients have vision damage or have to stop ...

Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £16.90.

Graham Parry, an analyst from Bank of America Securities, maintained the Sell rating on GlaxoSmithKline (GSK – Research Report). The associated ...

The arrest in the slaying of UnitedHealthcare CEO Brian Thompson was the first step to putting his alleged killer behind bars ...

CHELMSFORD, MA / ACCESSWIRE / December 10, 2024 / Harte Hanks, Inc. (NASDAQ:HHS), the 101-year-old Massachusetts-based global customer experience company, today announced it's collaborating with Reddy ...

Mepolizumab, a biologic approved for asthma, is not currently approved for COPD, but data from a 2017 study showed a trend ...

The LATAM pain management drugs market was valued at $2,683.82 million in 2019, and is projected to reach $3,383.20 million by 2027, registering a CAGR of 3.5% from 2020 to 2027. The length of pain ...

Market analysts liked the news, with analysts for Cantor writing that this was a “best-case data update.” ...

GSK (GSK) reported a study showed its drug belantamab mafodotin was able to reduce the risk of death by 42% in certain ...